Cargando…
Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
In myelodysplastic syndrome (MDS), resistance to hypomethylating agents (HMA) portends a poor prognosis, underscoring the importance of understanding the molecular mechanisms leading to HMA-resistance. In this study, P39 and Kasumi-1 cells and their azacitidine-resistant and decitabine-resistant sub...
Autores principales: | Lee, Paul, Yim, Rita, Miu, Kai-Kei, Fung, Sin-Hang, Liao, Jason Jinyue, Wang, Zhangting, Li, Jun, Yung, Yammy, Chu, Hiu-Tung, Yip, Pui-Kwan, Lee, Emily, Tse, Eric, Kwong, Yok-Lam, Gill, Harinder |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144309/ https://www.ncbi.nlm.nih.gov/pubmed/35628480 http://dx.doi.org/10.3390/ijms23105670 |
Ejemplares similares
-
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
por: Lee, Paul, et al.
Publicado: (2021) -
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
por: Yung, Yammy, et al.
Publicado: (2021) -
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy
por: Gill, Harinder, et al.
Publicado: (2016) -
DNA hypomethylation silences antitumor immune genes in early prostate cancer and CTCs
por: Guo, Hongshan, et al.
Publicado: (2023) -
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)